• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Insulet expects delays in FDA review for Omnipod 5 with launch pushed back

December 6, 2021 By Sean Whooley

Insulet OmniPod 5
The Insulet Omnipod 5 [Photo courtesy of Insulet]
The highly anticipated launch of the Insulet (NSDQ:PODD) Omnipod 5 may not come as soon as thought as an FDA review drags on.

SeekingAlpha reported that Insulet CEO Shacey Petrovic, speaking at the Nasdaq Investor Conference, said the regulatory agency will likely not complete its review of the next-generation Omnipod 5 before the end of the year, meaning the launch projected for the fourth quarter of 2021 is now expected for the first quarter of 2022.

When the report came out Friday afternoon, shares of PODD were down 10.6%, but have since rebounded slightly and are trading up 0.5% at $264.54 per share.

News of a delay comes after Petrovic told Drug Delivery Business News this fall that the company anticipated FDA clearance for Omnipod 5 this year, then said in the company’s third-quarter earnings report last month that Insulet remained on track for the regulatory nod for the wearable automated insulin delivery technology by the end of the year.

Omnipod 5 offers a number of market-firsts, Petrovic said, building upon the Omnipod DASH, which was cleared in 2019. With pairing to Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 will be the first tubeless, wearable, automated insulin delivery system.

Patients will be able to use a dedicated handheld controller or control the system with a secure app on their smartphone, marking another first, according to the CEO. Recent data presented at the European Association for the Study of Diabetes (EASD) 2021 annual meeting demonstrated significantly improved time in range and reduced levels of glycosylated hemoglobin (HbA1c) in a clinical trial.

According to SeekingAlpha’s report, analysts cited the Omnipod 5 as critical for Insulet’s growth, with news of the delay likely alerting others across the industry to the risk of regulatory slowdowns, while one analyst told the outlet that it could boost rivals in the insulin delivery space, including Tandem Diabetes Care.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Wall Street Beat Tagged With: FDA, Insulet, Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS